Edwards Lifesciences stock holds above $90 as Q2 growth tops forecasts
Published on 08/25/2026 at 22:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Edwards Lifesciences (ISIN US28176E1082) stock is trading close to $90 in late August 2026 after the company delivered double-digit second-quarter revenue growth and earnings per share ahead of market forecasts, with new institutional positions reinforcing demand for the shares. Per recent market data as of August 24, 2026, the stock closed at $90.50, putting it within less than $6 of its 1-year high of $96.29 and leaving limited distance to the average analyst target above $100. Recent coverage highlights how the latest quarterly report and fresh guidance are shaping expectations.
Q2 2026 earnings beat and guidance
In its most recent reported quarter, Q2 2026, Edwards Lifesciences generated revenue of $1.74 billion, representing 13.6% year-over-year growth, underscoring solid demand in its structural heart and critical care franchises. The same summary notes that earnings per share in the quarter reached $0.78, exceeding a consensus estimate of $0.74 by $0.04.
Management also provided an outlook for Q3 2026 and the full year that investors are using as a valuation anchor. For the third quarter of 2026, the company guided earnings per share to a range of $0.71 to $0.77, while the full-year 2026 earnings outlook was set between $2.95 and $3.05 per share, according to the latest brief. Compared with the Q2 2026 earnings print of $0.78 per share, the Q3 guidance midpoint of $0.74 suggests a modest sequential step down but still implies healthy profitability on a year-over-year basis.
This combination of double-digit revenue expansion and a four-cent earnings beat has helped support the current valuation. With full-year 2026 earnings guidance peaking at $3.05 per share, the closing price of $90.50 on August 24, 2026, points to a forward price-to-earnings multiple in the low 30s at the top of the range, a level that reflects expectations for continued growth in high-margin heart valve and monitoring products.
Institutional interest and analyst consensus
New filings indicate that institutional investors continue to build positions in Edwards Lifesciences, adding a supportive ownership backdrop. One recent disclosure shows that an institutional investor acquired 65,538 shares in the second quarter of 2026, an investment valued at $5.9 million based on transaction prices reported in the filing. Additional data indicate that another asset manager purchased 35,500 shares in the same period for $3.2 million, helping lift institutional ownership to 79.46% of the share float.
High institutional participation can add both liquidity and scrutiny, and in Edwards Lifesciences case it aligns with a constructive analyst stance. Across recent research coverage compiled in the same overviews, the shares carry an average rating described as Moderate Buy, with a consensus price target of $100.27. Against the stock’s $90.53 opening level cited in one of the summaries, that target implies upside of roughly 10.8%, while the proximity of the current price to the 1-year high of $96.29 shows that investors have already priced in a portion of the growth story.
Insider transactions provide another piece of context. Over the last 90 days, company insiders sold 25,570 shares with an aggregate value of $2,219,390, according to the same filings. While insider selling does not automatically signal a negative view, the fact that institutional investors are simultaneously adding exposure offers a contrast between long-term portfolio accumulation and individual liquidity events.
Share performance and trading levels
Recent trading data show that Edwards Lifesciences has been relatively steady in the weeks leading up to late August 2026. Historical prices compiled for the stock indicate that on August 24, 2026, Edwards Lifesciences closed at $90.50 after trading in an intraday range from $89.46 to $91.11, on volume of 2.72 million shares. The same price history lists an opening print of $89.89 for that session, with the daily gain calculated at 0.79%.
The broader technical picture described in recent commentaries points to supportive moving averages. According to these summaries, Edwards Lifesciences shares trade with a 50-day moving average of $89.30 and a 200-day moving average of $84.74, placing the latest close both above the intermediate trend line and meaningfully above the longer-term average. The stock’s 1-year low stands at $72.30, while the 1-year high is $96.29, so the current level leaves it roughly 25% above the low and roughly 6% below the high.
From an investor perspective, these levels create a clear band to watch. A sustained move above the 1-year high could reinforce the positive read-through from Q2 2026 growth and the full-year guidance range, while a retreat toward the 50-day average would test how durable the recent institutional buying interest proves to be. The roughly 10-point gap between the latest closing price of $90.50 and the consensus target of $100.27 underlines that expectations remain constructive, but not euphoric, compared with some higher-multiple growth peers in the medical technology space.
Heart valve technology at the core
Edwards Lifesciences is best known for its transcatheter heart valve systems and related technologies for treating structural heart disease. Its portfolio includes minimally invasive aortic valve replacement systems designed to help patients who face elevated risks with open-heart surgery, as well as specialized valves and repair devices used in mitral and tricuspid procedures. The company also markets critical care monitoring systems that provide real-time hemodynamic data in operating rooms and intensive care units, complementing its interventional cardiology offerings.
The revenue contribution from these product lines underpins the double-digit growth rates reported in Q2 2026. Demand for minimally invasive heart valve procedures has been supported by aging populations, expanded indications, and evolving clinical data, while hospitals value technology that can both improve outcomes and manage resource constraints. For Edwards Lifesciences, continued investment in clinical trials and device innovation is critical to sustaining its earnings guidance trajectory for 2026 and beyond.
Edwards Lifesciences stock at a glance
Edwards Lifesciences shares trade on the New York Stock Exchange under the ticker EW, giving US investors straightforward access to the company’s structural heart and critical care growth story. Based on the latest available data for August 24, 2026, the stock closed at $90.50, with an intraday trading range between $89.46 and $91.11 in that session. At that price, the shares sit within a corridor bounded by a 1-year low of $72.30 and a 1-year high of $96.29, and they remain modestly below the consensus price target of $100.27 described in recent analyst overviews.
Read more
More on Edwards Lifesciences stock and its latest financial guidance can be found in the company’s investor information and recent market data summaries.
Transcatheter heart valve franchise
A core driver of Edwards Lifesciences performance is its transcatheter heart valve franchise, which offers devices that enable physicians to replace diseased aortic valves through a catheter-based approach rather than open-heart surgery. These systems are designed to shorten hospital stays and recovery times while addressing severe aortic stenosis in patients who may not be candidates for traditional surgery. Ongoing innovation in valve design, delivery systems, and expanded clinical indications helps support the revenue growth trend reflected in the Q2 2026 figures discussed in recent earnings coverage.
Stock conclusion and latest price context
Edwards Lifesciences stock, listed on the New York Stock Exchange under the ticker EW, last closed at $90.50 on August 24, 2026, in US trading, based on compiled historical data for that date. That closing level leaves the shares below both their 1-year peak of $96.29 and the consensus target of $100.27, but above key moving averages, reflecting a market view that balances solid recent execution with expectations for continued growth in the company’s heart valve and critical care businesses.
Fact box
Company: Edwards Lifesciences Corp.
ISIN: US28176E1082
Ticker: EW
Exchange: NYSE
Price (as of August 24, 2026, 4:00 p.m. ET): $90.50 USD
Sector / Industry: Health care / Medical devices
Index membership: S&P 500
